Abstract
A phase I trial of interleukin-2 and interferon gamma combination treatment in patients with advanced malignancies was performed based on preclinical in vitro and in vivo data which demonstrated synergistic antitumor effect. The toxicities, immune parameters, and tumor responses are described. The clinical and biologic maximal tolerated doses were extrapolated from these data.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Drug Evaluation
-
Female
-
Humans
-
Immune System / drug effects
-
Interferon-gamma / administration & dosage*
-
Interferon-gamma / adverse effects
-
Interleukin-2 / administration & dosage*
-
Interleukin-2 / adverse effects
-
Male
-
Middle Aged
-
Neoplasms / drug therapy*
-
Recombinant Proteins / adverse effects
-
Recombinant Proteins / therapeutic use
Substances
-
Interleukin-2
-
Recombinant Proteins
-
Interferon-gamma